Ghadimi-Moghadam, A, Haghani, M, Bevelacqua, J J, Jafarzadeh, A, Kaveh-Ahangar, A, Mortazavi, S M J, Ghadimi-Moghadam, A, Mortazavi, S A R. (1399). COVID-19 Tragic Pandemic: Concerns over Unintentional “Directed Accelerated Evolution” of Novel Coronavirus (SARS-CoV-2) and Introducing a Modified Treatment Method for ARDS. سامانه مدیریت نشریات علمی, 10(2), 241-246. doi: 10.31661/jbpe.v0i0.2003-1085
A Ghadimi-Moghadam; M Haghani; J J Bevelacqua; A Jafarzadeh; A Kaveh-Ahangar; S M J Mortazavi; A Ghadimi-Moghadam; S A R Mortazavi. "COVID-19 Tragic Pandemic: Concerns over Unintentional “Directed Accelerated Evolution” of Novel Coronavirus (SARS-CoV-2) and Introducing a Modified Treatment Method for ARDS". سامانه مدیریت نشریات علمی, 10, 2, 1399, 241-246. doi: 10.31661/jbpe.v0i0.2003-1085
Ghadimi-Moghadam, A, Haghani, M, Bevelacqua, J J, Jafarzadeh, A, Kaveh-Ahangar, A, Mortazavi, S M J, Ghadimi-Moghadam, A, Mortazavi, S A R. (1399). 'COVID-19 Tragic Pandemic: Concerns over Unintentional “Directed Accelerated Evolution” of Novel Coronavirus (SARS-CoV-2) and Introducing a Modified Treatment Method for ARDS', سامانه مدیریت نشریات علمی, 10(2), pp. 241-246. doi: 10.31661/jbpe.v0i0.2003-1085
Ghadimi-Moghadam, A, Haghani, M, Bevelacqua, J J, Jafarzadeh, A, Kaveh-Ahangar, A, Mortazavi, S M J, Ghadimi-Moghadam, A, Mortazavi, S A R. COVID-19 Tragic Pandemic: Concerns over Unintentional “Directed Accelerated Evolution” of Novel Coronavirus (SARS-CoV-2) and Introducing a Modified Treatment Method for ARDS. سامانه مدیریت نشریات علمی, 1399; 10(2): 241-246. doi: 10.31661/jbpe.v0i0.2003-1085
COVID-19 Tragic Pandemic: Concerns over Unintentional “Directed Accelerated Evolution” of Novel Coronavirus (SARS-CoV-2) and Introducing a Modified Treatment Method for ARDS
1MD, Pediatric Infectious Ward, Yasuj University of Medical Sciences, Yasuj, Iran
2PhD, Department of Radiology, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran
3PhD, Bevelacqua Resources, Richland, Washington 99352, United States
4PhD, Department of Immunology, Faculty of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran
5MSc, Vice-chancellery for Research, Shiraz University of Medical Sciences, Shiraz, Iran
6PhD, Medical Physics and Engineering Department, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
7PhD, Diagnostic Imaging Department, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, United States
8BSc, Faculty of Medicine, Szeged University, Szeged, Hungary
9MD, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
چکیده
Global health authorities are trying to work out the current status of the novel coronavirus (COVID-19) outbreak and explore methods to reduce the rate of its transmission to healthy individuals. In this viewpoint we provide insights concerning how health care professionals can unintentionally shift the novel coronavirus type to more drug-resistant forms. It is worth noting that viruses usually have different sensitivities to physical and chemical damaging agents such antiviral drugs, UV and heat ranging from extremely sensitive (ES) to extremely resistant (ER) based on a bell-shaped curve. Given this consideration, the widespread infection of people with such ER viruses would be a real disaster. Here, we introduce a modified treatment method for COVID-19-associated pneumonia. In this proposed method, COVID-19 patients will receive a single dose of 100, 180 or 250 mSv X-ray radiation that is less than the maximum annual radiation dose of the residents of high background radiation areas of Ramsar that is up to 260 mSv. In contrast with antiviral drugs, a single dose of either 100, 180 or 250 mSv of low LET X-rays cannot exert a significant selective pressure on the novel coronavirus (SARS-CoV-2) and hence does not lead to directed accelerated evolution of these viruses. Moreover, Low Dose Radiation (LDR) has the capacity of modulating excessive inflammatory responses, regulating lymphocyte counts, and controling bacterial co-infections in patients with COVID-19.
He F, Deng Y, Li W. Coronavirus Disease 2019 (COVID-19): What we know? J Med Virol. 2020;14(10):25766. doi: 10.1002/jmv.25766. PubMed PMID: 32170865.
Singhal T. A Review of Coronavirus Disease-2019 (COVID-19). Indian J Pediatr. 2020;87(4):281–6. doi: 10.1007/s12098-020-03263-6.
Sun P, Lu X, Xu C, Sun W, Pan B. Understanding of COVID-19 based on current evidence. J Med Virol. 2020;25(10):25722. doi: 10.1002/jmv.25722.
Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020;14(1):72-3.
Tsai J, Wilson M. COVID-19: a potential public health problem for homeless populations. Lancet Public Health. 2020;11(20):30053-0. doi: 10.1016/S2468-2667(20)30053-0.
Sohrabi C, Alsafi Z, O’Neill N, Khan M, Kerwan A, Al-Jabir A, Iosifidis C, Agha R. World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19). Int J Surg. 2020;76:71-76. doi: 10.1016/j.ijsu.2020.02.034. PubMed PMID: 32112977.
Kucharski AJ, Russell TW, Diamond C, Liu Y, Edmunds J, Funk S, et al. Early dynamics of transmission and control of COVID-19: a mathematical modelling study. Lancet Infect Dis. 2020;11(20):30144-4. doi: 10.1016/S1473-3099(20)30144-4. PubMed PMID: 32171059.
World Health Organization. Rolling updates on coronavirus disease (COVID-19). WHO; 2020.
Li H, Wang YM, Xu JY, Cao B. Potential antiviral therapeutics for 2019 Novel Coronavirus. Zhonghua Jie He He Hu Xi Za Zhi. 2020;43(3):170-2.
Kumari A, Simon SS, Moody TD, Garnett-Benson C. Immunomodulatory effects of radiation: what is next for cancer therapy? Future Oncol. 2016;12(2):239-56. doi: 10.2217/fon.15.300. PubMed PMID: 26621553. PubMed PMCID: PMC5479357.
Walle T, Martinez Monge R, Cerwenka A, Ajona D, Melero I, Lecanda F. Radiation effects on antitumor immune responses: current perspectives and challenges. Ther Adv Med Oncol. 2018;10:1758834017742575. doi: 10.1177/1758834017742575. PubMed PMID: 29383033. PubMed PMCID: PMC5784573.
Yang G, Kong Q, Wang G, Jin H, Zhou L, Yu D, et al. Low-dose ionizing radiation induces direct activation of natural killer cells and provides a novel approach for adoptive cellular immunotherapy. Cancer Biother Radiopharm. 2014;29(10):428-34. doi: 10.1089/cbr.2014.1702. PubMed PMID: 25402754. PubMed PMCID: PMC4267769.
Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol. 2020. doi: 10.12932/AP-200220-0772.
Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and diagnosis of COVID-19. Journal of Pharmaceutical Analysis. 2020. doi: 10.1016/j.jpha.2020.03.001.
Schroder S, Kriesen S, Paape D, Hildebrandt G, Manda K. Modulation of Inflammatory Reactions by Low-Dose Ionizing Radiation: Cytokine Release of Murine Endothelial Cells Is Dependent on Culture Conditions. Journal of immunology research. 2018;2018:2856518. doi: 10.1155/2018/2856518.
Rodel F, Frey B, Manda K, Hildebrandt G, Hehlgans S, Keilholz L, et al. Immunomodulatory properties and molecular effects in inflammatory diseases of low-dose x-irradiation. Front Oncol. 2012;2:120. doi: 10.3389/fonc.2012.00120. PubMed PMID: 23057008. PubMed PMCID: PMC3457026.